MDGL
MADRIGAL PHARMACEUTICALS, INC.
Key Financials
Net Income
$-288284000
↑ 38.1%
Operating Income
$-300097000
↑ 39.7%
EPS (Diluted)
$-12.85
↑ 41.3%
Revenue
$958.4M
↑ 432.1%
Total Assets
$1.3B
↑ 20.9%
Total Liabilities
$656.9M
↑ 128.2%
Cash & Equivalents
$198.7M
↑ 98.7%
Shareholders' Equity
$602.7M
↓ 20.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 3/27/2026 | View on SEC |
| 4 | 3/6/2026 | View on SEC |
| 144 | 3/6/2026 | View on SEC |
| 4 | 3/6/2026 | View on SEC |
| 144 | 3/6/2026 | View on SEC |
| 4 | 3/6/2026 | View on SEC |
| 144 | 3/6/2026 | View on SEC |
| 4 | 3/6/2026 | View on SEC |
| 144 | 3/6/2026 | View on SEC |
| 4 | 3/6/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | MDGL |
| Company Name | MADRIGAL PHARMACEUTICALS, INC. |
| CIK | 1157601 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 404-380-9263 |